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Renal cell carcinomas, although usually apparently fully resected at surgery, commonly recur as distant metastasis. New markers are
needed to predict which patients may relapse especially as novel methods of treatment (e.g. laproscopic resection) may make it
impossible to assess conventional pathological prognostic markers. The caveolins are a family of proteins that represent the major
structural components of caveolae; recent work suggests that these may have influence on several signalling pathways and they are
thus potential prognostic markers. Immunohistochemistry for caveolin-1 was performed on sections of peripheral tumour from 114
consecutative nonmetastatic RCCs. Cytoplasmic caveolin-1 immunohistochemical (ICC) reaction was scored on a semiquantative
scale of 1–3. Immunohistochemical score was tested for impact on disease-free survival by Kaplan–Meier and Cox regression
methods. A total of 50 tumours had ICC score 1; 43 had score 2 and 21 score 3. Larger, higher grade and tumours with vascular
invasion had significantly higher scores. On univariate survival analysis (Kaplan–Meier), patients with tumours scoring 1 had a mean
disease-free survival of 6.61 years (95% CI 5.76–7.46) compared with 5.4 years (4.53–6.30) and 3.15 years (1.87–4.44) for scores 2
and 3, respectively. This is a significant difference (P¼0.0017 log rank test). On multivariate analysis with size, grade and caveolin ICC
score as independent covariates, caveolin ICC score 3 was an influential predictor of poor disease-free survival with a hazard ratio of
2.6 (P¼0.03). We conclude that cytoplasmic overexpression of caveolin-1 predicts a poor prognosis in RCC; that this is likely to be a
useful prognostic marker and that it may have importance in tumour progression.
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Renal cell carcinoma (RCC) is the most common malignancy of the
kidney and is responsible for 3% of all cancers in adults and about
2% of cancer-related deaths (Dhote et al, 2000). At presentation,
about two-thirds of RCCs are clinically localised and as a result
such patients will usually undergo nephrectomy. Unfortunately,
following surgical resection, approximately 40% of patients treated
for apparently localised disease will relapse and die as a result of
distant metastasis (Ljungberg et al, 1999). Assessment of the risk of
developing subsequent metastatic disease is notoriously difficult,
and currently accepted prognostic indicators are recognised as not
offering the accuracy required for confident prognostication and
selection of patients for further therapy. It is clear that the
identification of additional prognostic markers will be of benefit to
the selection of high-risk patients for adjuvant therapy, particu-
larly as novel methods of treatment, for example laproscopic
resection may, by morcellating the resected tumour, make it
impossible to determine all conventional pathological prognostic
parameters (Rabban et al, 2001).
The caveolins are an evolutionary conserved family of
proteins that represent the major structural and functional
components of caveolae, which are specialised invaginated lipid
microdomains present at the plasma membrane of most mamma-
lian cells (Razani et al, 2002). Caveolin-1 was the first of the
caveolin supergene family to be discovered over a decade ago and
as a result remains the most extensively studied. Caveolin-1 was
first identified as a novel substrate for the src kinase oncogene in
virally transformed fibroblasts (Glenney, 1989). Since then several
functions have been ascribed to caveolae and caveolin, including
the compartmentalisation of members of numerous signalling
cascades. This allows crosstalk between distinct linear signalling
pathways and the negative regulation of the kinase activity of
several key signalling molecules. Among others, these include the
epidermal and platelet growth factor receptors, p42/p44 MAP
kinases, heterotrimeric G-proteins, Src family tyrosine family
kinases and nitric oxide synthases (Shaul and Anderson, 1998).
Additionally, the expression of recombinant caveolin-1 is sufficient
to restrict the growth potential of transformed cells isolated from
primary tumours of the breast (Lee et al, 1998), lung (Racine et al,
1999) and ovaries (Bagnoli et al, 2000). In this regard, caveolin-1 is
proposed to represent a novel tumour suppressor protein.
Consistent with this the chromosomal loci of caveolin-1 and -2
has been recently identified as 7q31.1 (Engelman et al, 1999), a
fragile site frequently deleted in a wide spectrum of human cancers
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ythat includes cases of sporadic RCC. Such chromosomal rearrange-
ments may result in translocations, deletions or amplification of
genes at this locus (Shridhar et al, 1997), although the functional
significance of such changes on caveolin in RCC remain to be
determined.
However, much of the current literature that lends support for
caveolin-1 serving as a tumour suppressor protein has been
generated by the use of in vitro and ex vivo overexpression systems
for caveolin-1 that are assumed to mimic the activity of
endogenously expressed caveolin. To this end a recent series of
clinicopathological studies have determined that the upregulation
of caveolin-1 is indeed associated with tumour progression and/or
poor prognosis in several distinct cancers such as adenocarcino-
mas of the prostate (Yang et al, 1999), lung (Ho et al, 2002),
pancreas (Ho et al, 2002) and squamous cell carcinoma of the
oesophagous (Ho et al, 2002).
There are no previous studies of renal cancer and caveolin. We
have therefore designed and carried out a study in which we
examined the immunohistochemical (ICC) detected expression of
caveolin-1 in 114 RCCs from patients treated for localised disease,
and assessed its impact on disease-free survival. The aim of the
study is to determine if caveolin-1 expression might have value as
a prognostic marker and if it has a potential role in tumour
progression.
PATIENTS AND METHODS
Patient selection
The tumours studied were a consecutive series of RCCs
identified from the pathological records of one hospital. This
is a subset (from one hospital) of a series that has been reported
in detail previously (Griffiths et al, 2002). All patients had
undergone surgery for a primary kidney tumour and none had
evidence of either lymph node or distant metastatic disease
either before or at surgery. Histology reports and slides were
available in all cases and all included at least two blocks of the
edge of the tumour and a block of renal vessels. Each tumour
slide was reviewed by a pathologist without knowledge of the
clinical outcome and assessed for histological type by the
Heidelberg classification (Kovacs et al, 1997); for Fuhrman nuclear
grade (Fuhrman et al, 1982); the presence or absence of any
vascular invasion (either microvascular invasion, renal vein
invasion or inferior vena cava invasion); and whether or not there
was capsular penetration with cellular invasion of perinephric fat
(Thomas et al, 2003).
The median age of the 114 patients was 63.6 years (range
33–84); 76 were men and 38 women; 69 of the tumours were
clear cell carcinomas, 17 papillary carcinomas, four chromophobe
carcinomas and there was one collecting duct carcinoma. A
total of 23 of the tumours were unclassified by conventional
histology. Most of the patients had been reviewed annually as
outpatients for between 3 and 7 years. The following information
was obtained from the patients notes: date of birth, sex, date of
surgery, date last seen, date of death, cause of death and the date
on which recurrent or metastatic disease was first identified. Two
cases were lost to follow-up at 25 and 29 months. In all other
survivors, the last recorded clinical contact was after 1 January 98,
giving a median follow-up of 44 months (range 1–99). In nine
patients in whom the cause of death was recorded as renal
cell cancer, the date of first recurrence was not available; in these
cases, the date of death was considered the end point for disease-
free survival.
Paraffin blocks were available in all cases, and for each renal
carcinoma a block was selected that contained a sample
of peripheral tumour. Sections were cut onto cleaned slides
(Superfrost Plust)a t4mm thickness.
Antibodies and reagents
The rabbit polyclonal anti-caveolin-1 was obtained from BD
Transduction Laboratories (Oxford, UK). This antibody recognises
both the a and b isoforms of caveolin-1 as assessed by Western
blotting. The secondary swine anti-rabbit horseradish peroxidase
(HRP)-conjugated antibody, as well as nonimmune rabbit serum
were obtained from DAKO (Cambridge, UK)
Immunohistochemistry
Immunohistochemical staining for caveolin-1 was carried out
using standard methodologies as previously described (Campbell
et al, 2002). Briefly, following removal of paraffin wax, endogenous
peroxidase activity within the rehydrated sections was blocked
with 0.6% hydrogen peroxide in methanol for 15min at room
temperature. The slides were then briefly washed in tap water
before each section was equilibrated in Optimaxt wash buffer (pH
7.4; Menerium Diagnostics, Oxford UK) at room temperature for
an additional 10min. After draining, the primary antibody was
applied to each section at a dilution of 1:10 (diluent was 0.6% BSA
in Optimaxt wash buffer) and incubated overnight at 41C for a
total of 15h. The next day, sections were washed (4 1min) with
Optimaxt buffer and the appropriate secondary HRP-conjugated
antibody was applied at a dilution of 1:100 for 1h at room
temperature. Following this further washes were undertaken to
remove any unbound reporter antibody, and immunoreactivity
was subsequently detected using the 3,30-diaminobenzidine system
(Sigma, Poole, Dorset, UK). The sections were counterstained with
haematoxylin and finally mounted.
Controls and scoring of stained specimens
Negative controls run in parallel comprised sections where the
primary antibody had been omitted or replaced with nonimmune
rabbit serum. Caveolin-1 staining of peripheral endothelial cells
and nephric fat within the sections was monitored and served as
positive internal control stain for immunoreactivity.
Scoring of sections was performed by a pathologist (DFRG) and
a research associate (LC). Caveolin-1 staining was assessed by light
microscopy using a double-headed microscope without knowledge
of the clinical outcome, and each tumour was allocated a score by
consensus in a semiquantitative way against tabulated criteria as
follows: 0: no detectable deposit in tumour cells; 1: very light
diffuse or focal light deposit in tumour cell cytoplasm; 2: light
diffuse or moderate focal deposit (but may include very small areas
of heavy deposit); 3: tumour containing areas of heavy deposit in
tumour cells. Only two tumours scored zero and these cases were
pooled with score 1 for subsequent analysis.
Statistics
Correlations between variables were examined by crosstabulation
and w
2 testing and Spearman correlation as appropriate. For
disease-free survival, deaths due to causes other than RCC were
considered to be censored at the date of death. Univariate analysis
of disease-free survival was carried out by the Kaplan–Meyer
method using the Log rank test. Multivariate survival analysis was
carried out by Cox regression; in the case of grade, capsular
invasion, vascular invasion and caveolin-1 score, a linear contrast
was employed such that comparison was made with grade 1,
caveolin score of 1, and the absence of vascular and capsular
invasion, respectively. Initially, all covariates were entered into the
model; covariates for the final model were selected by a forward
conditional method with the probability of entry of 0.10 and of
rejection of 0.15. A second Cox regression analysis was carried out
entering only the variables that would be available following a
laproscopic resection in which the tumour had been morcellated,
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ythat is, excluding capsular invasion and vascular invasion. All
statistical analysis was carried out using the program SPSS for
Windows 9.0, (SPSS Inc, Chicago, IL, USA). Where appropriate, all
tests of significance were two-tailed.
RESULTS
In normal renal parenchyma (adjacent to some of the tumours),
the strongest ICC staining for caveolin-1 was localised to proximal
tubular epithelium cytoplasm in a fine granular pattern. Similar
but weaker staining was seen in distal tubules, the medullary
tubules and capsular glomerular epithelium. Strong staining was
also noted in the endothelium of arteries, arterioles and the vasa
recta. However, no staining was seen in the podocytes, the
glomerular capillaries or the peritubular capillaries. There was
consistently strong staining of the cell membrane of the adipocytes
in the renal sinus.
Two tumours, both well-differentiated conventional RCCs,
showed predominant cell membrane staining. This was not seen
in others and was ignored for the purposes of this study. In the
remainder, the localisation and the nature of staining, if present ,
was granular and cytoplasmic and qualitatively similar to that seen
in the normal proximal tubule (Figure 1). In all, 50 cases were
scored for staining intensity semiquantativly as 0 or 1; 43 cases as
score 2 and 21 as score 3. In practice, tumours with score 3 had
substantial areas of tumour cells with heavy cytoplasmic deposit.
The crosstabulation of the scores and the other prognostic
determinants is shown in Table 1. More intense caveolin staining
was found significantly more frequently in high-grade tumours,
and in tumours showing any vascular invasion (Pearson’s w
2
P¼0.008 and 0.003, respectively). When analysed for level of
vascular invasion, there was a significant trend to increasing
caveolin-1 expression with more advanced vascular invasion
(Table 2).
Survival analysis showed that tumours with more caveolin
staining had shorter time to tumour recurrence. On univariate
survival analysis (Kaplan–Meier), patients with tumours scoring 1
had a mean disease-free survival of 6.61 years (95% CI 5.76–7.46)
compared with 5.4 years (4.53–6.30) and 3.15 years (1.87–4.44) for
AB
CD
Figure 1 Caveolin-1 immunohistochemistry of kidney and renal tumours. (A) Normal kidney showing granular immunoreactivity in the proximal tubular
cells endothelium of arterioles and capsular epithelium; (B) RCC with score 1, note the strong vascular immunoreactivity; (C) RCC with caveolin score 2
and (D) high-grade sarcomatoid RCC in the lower left part of the image with caveolin score 3.
Table 1 Crosstabulation of prognostic indices and caveolin-1 score
Caveolin-1 score
1.0 2.0 3.0 Total
Prognostic indices n¼50 n¼43 n¼21 n¼114 Statistics
Tumour Grade 1 and 2 37 33 9 79 P¼0.008
Tumour Grade 3 13 6 9 28
Tumour Grade 4 4 3 7
Tumour size o5cm 16 11 4 31 P¼0.133
Tumour size 5–7cm 15 12 2 29
Tumour size 47cm 19 20 15 53
Vascular Invasion ( ve) 36 24 6 66 P¼0.003
Vascular Invasion (+ve) 14 19 15 48
Capsular Invasion ( ve) 43 35 15 93 P¼0.352
Capsular Invasion (+ve) 7 8 6 21
Caveolin expression in renal cell carcinoma
L Campbell et al
1911
British Journal of Cancer (2003) 89(10), 1909–1913 & 2003 Cancer Research UK
M
o
l
e
c
u
l
a
r
a
n
d
C
e
l
l
u
l
a
r
P
a
t
h
o
l
o
g
yscores 2 and 3, respectively (Figure 2). This is a significant
difference (P¼0.0017 log rank test). On Cox regression analysis,
including covariates tumour type, size, vascular invasion, capsular
invasion grade and caveolin score, the influential covariates
predicting relapse were grade, capsular invasion and vascular
invasion; the covariates caveolin score, tumour size and tumour
type being rejected by the selection criteria. However, in a Cox
regression model with the covariates size, grade, caveolin score
and tumour type, caveolin score is a significant influential
covariate together with tumour size and grade (Table 3).
DISCUSSION
We have shown that caveolin-1 overexpression, as determined by
immunocyochemistry, is an important prognostic determinant in
RCC. This is the first demonstration that caveolin-1 expression
correlates with outcome in RCC; this observation requires a
biological explanation and provides the opportunity to consider
potential clinical applications as a prognostic marker.
The relationship between positive caveolin-1 expression within
this particular patient cohort and other excepted clinicopatholo-
gical prognostic variables currently used in RCC is similar to other
pathological findings conducted on other tumour types. For
example, in prostate cancer, increased caveolin-1 expression
correlates with Gleason score, positive surgical margins, lymph
node metastasis and androgen insensitivity (Yang et al, 1999).
Additionally, caveolin-1 overexpression is related to tumour size
and histopathological stage in both pancreatic ductal carcinoma
(Suzuoki et al, 2002) and oesphageal squamous cell carcinoma
(Kato et al, 2002). In all instances, elevated caveolin- 1 levels were
associated with tumour progression and poor prognosis.
To date little is known about the precise function of caveolin-1
in the normal functioning of kidney, but it has been shown to be
present in collecting ducts (Tajika et al, 2002) and proximal tubule
cells (Edwards, 1999) of rat kidney, where it is shown to be
localised with the water protein channel aquaporin-2 and the
chloride channel huH1, respectively. These observations suggest a
role for caveolin-1 in the regulation of water reabsorption. In mice,
it has been colocalised with a calcium ATPase pump within the
plasma membrane of distal tubular cells where evidence implicates
a function related to calcium reabsorption (Cao et al, 2003). Our
findings suggest normal cytoplasmic localisation of caveolin-1 in
the proximal and distal tubules and capsular glomerular epithe-
lium in normal human kidney, but no apparent expression was
observed in podocytes, glomerular capillaries or peritubular
capillaries. However, our technique may not be sensitive enough
to identify low levels of membrane expression. Apparent from the
results of our current study was the cytoplasmic localisation of the
overexpressed caveolin-1 within the renal carcinoma cells. Such a
subcellular location as opposed to its more traditional position at
the plasma membrane appears to be a prevailing feature within
different types of human cancer where caveolin-1 levels are
elevated as is the case for tumours of the colon (Fine et al, 2001),
pancreas (Suzuoki et al, 2002) and prostate (Yang et al, 1999). This
suggests that, within the transformed cells, caveolin-1 is rerouted
into the secretory pathway of these cells, and that such an
inappropriate caveolin-1 localisation and/or accumulation may
contribute to the transformed phenotype. Indeed within prostate
cancer cell lines, caveolin-1 has been shown to be secreted in
response to androgens and glucocorticoids. This secreted caveolin
is sufficient to permit survival and clonal growth of these cells,
thereby contributing to their metastatic potential and androgen
insensitivity (Tahir et al, 2001). It is not clear if similar
mechanisms occur within the context of RCC. However, from
what is currently known from other studies, caveolin-1 may serve
as an important intercellular signalling molecule that is capable of
potentiating the progression, invasiveness and vascularisation of
renal tumours. In support of this hypothesis, caveolin-1 is shown
to interact and potentiate the activity of metalloproteinases
(Puyraimond et al, 2001) and the urokinase receptor (Stahl and
Mueller, 1995; Wei et al, 1999) in a variety of cell types, leading to
activation of cell surface plasminogen, and generation of plasmin,
which in turn leads to the overall degradation of extracellular
matrices. Recently, Lisanti and co-workers (Liu et al, 2002) have
shown that, within an in vitro model of angiogenesis, the direct
delivery of caveolin-1-derived peptides to the cytoplasm of
endothelial cells is sufficient to induce capillary tubule formation.
These findings are of significance since several independent
studies advocate that the presentation of angiogenesis and
microvascular invasion in patients who undergo surgery for RCC
are at high risk for developing metastatic disease (Van Poppel et al,
1997; Dekel et al, 2002; Griffiths et al, 2002). More work will be
required to determine whether or not caveolin-1 immunoreactivity
is a useful clinical marker. Our series is small, but nevertheless
Table 2 Level of vascular invasion crosstabulated with caveolin score
Caveolin
score o or 1
Caveolin
score 2
Caveolin
score 3
Microvascular
invasion
9 5 4 Spearman correlation
P¼0.038
Renal vein
invasion
38 5
IVC invasion 2 6 6
Years
9 8 7 6 5 4 3 2 1 0 −1
S
u
r
v
i
v
a
l
1.0
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0.0
Score 3
Score 2
Score 1
Figure 2 Kaplan–Meier disease-free survival plot of calveolin score
(P¼0.0017 log rank test).
Table 3 Cox regression analysis including tumour type (rejected by
selection criteria) tumour size, tumour grade and caveolin score
Hazard ratio 95% CI P
Grade 1 and 2 1
Grade 3 1.3 0.6–2.9 0.47
Grade 4 6 2.3–16.0 0.0003
Caveolin score 0 and 1 1
Cavolin score 2 1.4 0.6–3.2 0.43
Caveolin score 3 2.6 1.1–6.2 0.03
Size
a 1.17 1.05–1.29 0.003
aHazard ratio is for each increase in size by 1cm.
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predictor of poor disease-free survival. It will be important to
determine if this can be confirmed in other series, and if the effect
is similar in all tumour subtypes. With more cases it may be
possible to determine if caveolin-1 expression is an influential
covariate when all other known prognostic determinants are
included in the Cox model. Even if this is not the case, our analysis
shows that when vascular invasion and capsular invasion are
excluded, the hazard of caveolin score 3 is 2.6 times that of
caveolin score 1. This is similar to the hazard of the presence of
vascular invasion, an established and robust prognostic determi-
nant. It is also noted that caveolin-1 immunoreactivity positively
correlates with vascular invasion; our results therefore suggest that
caveolin immunoreactivity is likely to be of value in assessing
prognosis when it is not possible to assess vascular invasion. An
example of the latter would include laparoscopic nephrectomy for
the resection of renal tumours via a small incision in the
abdominal wall. Given that these incisions are typically
10–12mm in diameter, the removal of intact tumours in some
instances is impossible; this therefore requires in situ morcella-
tion, rendering assessment of vascular invasion difficult
(Rabban et al, 2001). Determination of the degree of caveolin-
1e x p r e s s i o ni nt h e s et u m o u rf r a g m e n t sm a yb eo fa d d i t i o n a l
value in the staging of renal tumours and assessment of
prognosis.
In summary, we have shown that elevated immunoexpression of
caveolin-1 is a predictor of poor disease-free survival in RCC,
suggesting that cell signalling pathways involving caveolin-1 may
have importance in tumour progression. Furthermore, the
strength of the association with poor prognosis and its association
with vascular invasion suggest a role in assessing prognosis for
clinical use.
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